Targeting the adenosine A2b receptor in the tumor microenvironment overcomes local immunosuppression by myeloid-derived suppressor cells

Emerging evidence suggests that the adenosine A2b receptor (ADORA 2B, also known as A2bR) plays a pivotal role in tumor progression. We have recently demonstrated that blocking A2bR stimulates T cell-mediated immunosurveillance in a melanoma model by impairing the influx of myeloid-deriver suppressor cells (MDSCs) into the tumor microenvironment. This results in robust antineoplastic effects, which can be abrogated by the adoptive transfer of MDSCs.